Abbott Laboratories (ABT) is drawing fresh scrutiny after sales declines in its Nutrition business, new product launches and pricing moves, and early signs of recovering volumes, all while analysts grow more cautious on the stock.

The share price has come under pressure despite the Exact Sciences acquisition and commentary around legal risks. The stock is down 16.83% on a 1 month share price return, and the 1 year total shareholder return has declined 36.06%, signaling fading momentum.

If this kind of pullback has you rethinking healthcare exposure, it could be a good moment to see what else is available via 32 healthcare AI stocks

So with Abbott trading well below analyst price targets, yet facing Nutrition pressures, Exact Sciences integration and legal overhangs, are you looking at a mispriced healthcare leader, or a stock where the market already sees limited future growth?

Most Popular Narrative: 25.8% Undervalued

According to the most followed narrative on Abbott, the fair value sits at $113.88 compared with the last close of $84.47, pointing to a sizable valuation gap.

Abbott Laboratories is a compelling growth investment with defensive qualities, supported by its market leadership, innovation-driven strategy, and diversified portfolio. While its premium valuation may limit near-term upside, the company’s strong fundamentals, exposure to high-growth markets, and commitment to shareholder returns make it a solid choice for investors with a medium- to long-term horizon.

Curious what justifies that fair value gap and growth label at the same time as a pullback on the chart? The narrative leans heavily on compound earnings, expanding margins and a future profit profile that treats Abbott more like a long duration growth story instead of a mature healthcare giant.

Result: Fair Value of $113.88 (UNDERVALUED)

However, this depends on Nutrition headwinds easing, and on the Exact Sciences deal and legal issues not putting additional pressure on earnings or investor confidence.

Next Steps

That mix of caution and optimism can feel confusing, so it helps to look at the full picture yourself and decide where you stand. To weigh both sides quickly, go through the 5 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Abbott has you rethinking your healthcare exposure, do not stop there. Broaden your watchlist with a few targeted stock ideas that fit different goals.

• Target potential bargains by scanning a focused list of 50 high quality undervalued stocks that combine quality with attractive pricing signals.
• Strengthen your income stream by reviewing 12 dividend fortresses built around higher-yield payouts and consistency.
• Prioritise resilience by checking 66 resilient stocks with low risk scores designed to highlight companies with lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.